Global Information
회사소개 | 문의 | 위시리스트

항생제 내성(AMR) 진단 시장, 전략, 동향(2018-2023년)

Antimicrobial Resistance Diagnostics Market, Strategies & Trends by Pathogen and Technology with Executive Guides and Customization 2018 to 2023

리서치사 Howe Sound Research
발행일 2019년 03월 상품 코드 654772
페이지 정보 영문 153 Pages
가격
US $ 5,995 ₩ 7,223,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 8,995 ₩ 10,838,000 PDF by E-mail (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 11,995 ₩ 14,453,000 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



항생제 내성(AMR) 진단 시장, 전략, 동향(2018-2023년) Antimicrobial Resistance Diagnostics Market, Strategies & Trends by Pathogen and Technology with Executive Guides and Customization 2018 to 2023
발행일 : 2019년 03월 페이지 정보 : 영문 153 Pages

세계의 항생제 내성(AMR : Antimicrobial Resistance) 진단 시장에 대해 조사했으며, 6개 주요 병원균에서의 기회, 발전하는 시장 예측, 주요 기업 20개사 개요 등의 정보를 전해드립니다.

제1장 서론과 시장 정의

제2장 동적인 시장 개요

  • 시장 진출 기업 : 역할과 영향
  • 항생제 내성(AMR)의 이해
  • 새로운 항생물질 및 기술에 도달하는 여정의 변화
  • 항생제 내성(AMR)에서 진단의 주요 역할

제3장 AMR의 시장 기회

  • AMR의 대규모 시장 기회
  • 진단 기술의 발전 기회
  • 항생물질 내성의 최근 발전

제4장 주요 바이오테크놀러지 기업과 그 기술

  • 진단

제5장 세계 시장

  • 세계 시장 : 국가별

제6장 세계 시장 : 병원균별

  • 세계 시장 : 병원균별
  • DRSP
  • DRC
  • CD
  • MRSA
  • DRNG
  • DRNTS

제7장 AMR 진단 : 기술별

  • 세계 시장 : 기술별
  • 박테리아 배양
  • 면역측정
  • PCR(중합효소 연쇄 반응)
  • 유전자 스크리닝
  • 질량분석계
  • 신속 검사, POC, 기타

제8장 AMR 진단의 향후 전망

KSM 18.07.02

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Table of Tables

  • Table 1 USA - Outpatient Use of Antibiotics by Class
  • Table 2 USA - Outpatient Use of Antibiotics Top 5
  • Table 3 Market Players by Type
  • Table 4 Known Human Pathogenic Diseases
  • Table 5 The Key Market Opportunities
  • Table 6 - Market Potential DRSP Diagnostic
  • Table 7 - Market Potential DRC Diagnostic
  • Table 8 - Market Potential CD Diagnostic
  • Table 9 - Market Potential CD Diagnostic
  • Table 10 Market Potential DRNG Diagnostic
  • Table 11 Market Potential DRNTS Diagnostic
  • Table 12 - Key AMR Diagnostics Issues
  • Table 13 The Global AMR Diagnostic Market by Country
  • Table 14 Global Market by Pathogen
  • Table 15 DRSP Diagnostics by Country
  • Table 16 DRC Diagnostics by Country
  • Table 17 CD Diagnostics by Country
  • Table 18 MRSA Diagnostics by Country
  • Table 19 DRNG Diagnostics by Country
  • Table 20 DRNTS Diagnostics by Country
  • Table 21 Global Market by Technology
  • Table 22 Culture Diagnostics by Country
  • Table 23 Immunoassay Diagnostics by Country
  • Table 24 PCR Diagnostics by Country
  • Table 25 NGS Diagnostics by Country
  • Table 26 MS Diagnostics by Country
  • Table 27 Rapid, POC and Other Diagnostics by Country

Table of Figures

  • Figure 1 Pharmaceutical Spending History by Country
  • Figure 2 AMR and Antibiotic Introduction
  • Figure 3 The Death Toll of AMR
  • Figure 4 AMR Diagnostics - Key Countries
  • Figure 5 Chart of Share Change by Pathogen
  • Figure 6 Chart - DRSP Diagnostics by Country
  • Figure 7 Chart - DRC Diagnostics by Country
  • Figure 8 Chart - CD Diagnostics by Country
  • Figure 9 Chart - Infectious Disease Immunoassay by Country
  • Figure 10 Chart - DRNG Diagnostics by Country
  • Figure 11 Chart - DRNTS Diagnostics by Country
  • Figure 12 Chart of Growth by Technology
  • Figure 13 Chart - Technology Change in Planning Period
  • Figure 14 Chart - Bacterial Culture by Country
  • Figure 15 Chart - Immunoassay Diagnostics by Country
  • Figure 16 Chart - PCR Diagnostics by Country
  • Figure 17 Chart - NGS Diagnostics by Country
  • Figure 18 Chart - MS Diagnostics by Country
  • Figure 19 Chart - Rapid, POC and Other Diagnostics by Country

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile 20 companies, large and small, working in this area.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research Seminar - Burke Institute

Finance for Senior Executives - Harvard Business School

Table of Contents

i. Antimicrobial Resistance - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
  • 1.2 Defining the Opportunity
    • 1.2.1 Revenue Market Size
  • 1.3 Methods and Sources
    • 1.3.1 Authors
    • 1.3.2 Sources
  • 1.4 U.S. Antibiotic Markets - Perspective
    • 1.4.1 U.S. Outpatient Use of Antibiotics
    • 1.4.2 U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market

  • 2.1 Market Players - Roles & Impacts
    • 2.1.1 Drug manufacturers - Larger/pharmaceutical
    • 2.1.2 Drug manufacturers - Generic
    • 2.1.3 Contract Research and Manufacturing
    • 2.1.4 In Vitro Diagnostics Industry
    • 2.1.5 Drug Marketing Companies
    • 2.1.6 Biotechnology Companies
    • 2.1.7 Regulatory Bodies
  • 2.2 Understanding Antimicrobial Resistance
    • 2.2.1 What is Antimicrobial Resistance (AMR)
    • 2.2.2 Bacteria and Other Microbes
    • 2.2.3 The History of Antibiotics
    • 2.2.4 The Role of Animal Husbandry
    • 2.2.5 The Implications of Horizontal Transfer
    • 2.2.6 The Threat of AMR
  • 2.3 The Changing Road to New Antibiotics & Technologies
  • 2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR

  • 3.1 The Key Large Market Opportunities in AMR
    • 3.1.1 Streptococcus Pneumoniae (DRSP)
    • 3.1.2 Campylobacter (DRC)
    • 3.1.3 Clostridium Difficile (CD)
    • 3.1.4 Staphylococcus aureus (MRSA)
    • 3.1.5 Neisseria gonorrhoeae (DRNG)
    • 3.1.6 Salmonella (DRNTS)
  • 3.2 Diagnostic Technology Development Opportunities
    • 3.2.1 What's Wrong with Microbiology
    • 3.2.2 The Features Battleground of Infectious Disease Diagnostics
    • 3.2.3 Multiplex vs. POC/Rapid
    • 3.2.4 The Miracle of Genetics
    • 3.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation
    • 3.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing.
    • 3.2.7 Markers of Resistance.
    • 3.2.8 What Happens to the Microbiology Lab?
  • 3.4. Antibiotic Resistance Recent Developments
    • Importance of These Developments
    • How to Use This Section
    • Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics
    • OpGen to File First 510(k) for AMR Gene Panel
    • Curetis' Subsidiary Ares Genetics Teams Up with Sandoz in Fight Against AMR
    • GeneCapture to determine antibiotic sensitivity in an automated rapid portable device
    • Quick identification of multidrug-resistant pathogens
    • OpGen to Offer Qiagen Nucleic Acid Purification Tech With Acuitas Pathogen Panel
    • Metagenomics Enables Researchers to Uncover Drug Resistance Genes
    • Rapid detection of multi-drug-resistant bacteria
    • Improved Diagnostics Fail to Halt the Rise of Tuberculosis
    • High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges
    • New solution for diagnosing antibiotic-resistant bacteria
    • MALDI-TOF - Results in Minutes not Days.
    • CRISPR Tool Used to Uncover Infections
    • Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
    • BD, Check-Points Receive CE Mark for Resistant Organism Screening Test
    • LiDia® BSI Detects Pathogens and Antimicrobial Resistance
    • New tool can Track Resistant Malaria
    • Rapid Test Developed to Measure Antibiotic Resistance in Patients with UTIs
    • Longitude Funds for POC Tests
    • New test can identify dangerous bacteria with resistance to last-resort antibiotic
    • bioMérieux receives FDA clearance for expanded pathogen identification capability
    • OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests
    • Hospital Plumbing Harbors Antibiotic Resistant Bacteria
    • Acquisition Strategy Fills Out Roche's Diagnostic Pipeline
    • Curetis Gets Singapore Approval for Pneumonia Test
    • PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx
    • Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies

4. Key Biotechnology Companies and Their Technology

  • 4.1 Diagnostics
    • 4.1.1 1928 Diagnostics
    • 4.1.2 Sense Biodetection.
    • 4.1.3 Fusion Genomics.
    • 4.1.4 Day Zero Diagnostics.
    • 4.1.5 Inflammatix
    • 4.1.6 Hutman Diagnostics
    • 4.1.8 bioMérieux Diagnostics
    • 4.1.9 Curetis N.V. / Curetis GmbH
    • 4.1.10 Great Basin Corporation
    • 4.1.11 Becton, Dickinson and Company
    • 4.1.12 Roche Diagnostics
    • 4.1.13 Cepheid (now Danaher)
    • 4.1.14 Atlas Genetics
    • 4.1.14 Accelerate Diagnostics
    • 4.1.15 Seimens
    • 4.1.16 Abbott Diagnostics
    • 4.1.17 Thermo Fisher
    • 4.1.18 Bio - Rad
    • 4.1.19 GenePOC Diagnostics
    • 4.1.20 Sysmex
    • 4.1.21 Ortho Clinical

5. The Global Market

  • 5.1 Global Market by Country

6. Global Market by Pathogens

  • 6.1 Global Market by Pathogens
  • 6.2 DRSP
  • 6.3 DRC
  • 6.4 CD
  • 6.5 MRSA
  • 6.5 DRNG
  • 6.6 DRNTS

7. AMR Diagnostics by Technology

  • 7.1 Global Market by Technology
  • 7.2 Bacterial Culture
  • 7.3 Immunoassay
  • 7.4 Polymerase Chain Reaction
  • 7.5 Genetic Sequencing
  • 7.6 Mass Spectrometer
  • 7.7 Rapid, POC and Other

8. Vision of the Future of AMR Diagnostics

Table of Tables

  • Table 1 USA - Outpatient Use of Antibiotics by Class
  • Table 2 USA - Outpatient Use of Antibiotics Top 5
  • Table 3 Market Players by Type
  • Table 4 Known Human Pathogenic Diseases
  • Table 5 The Key Market Opportunities
  • Table 6 - Market Potential DRSP Diagnostic
  • Table 7 - Market Potential DRC Diagnostic
  • Table 8 - Market Potential CD Diagnostic
  • Table 9 - Market Potential CD Diagnostic
  • Table 10 Market Potential DRNG Diagnostic
  • Table 11 Market Potential DRNTS Diagnostic
  • Table 12 - Key AMR Diagnostics Issues
  • Table 13 The Global AMR Diagnostic Market by Country
  • Table 14 Global Market by Pathogen
  • Table 15 DRSP Diagnostics by Country
  • Table 16 DRC Diagnostics by Country
  • Table 17 CD Diagnostics by Country
  • Table 18 MRSA Diagnostics by Country
  • Table 19 DRNG Diagnostics by Country
  • Table 20 DRNTS Diagnostics by Country
  • Table 21 Global Market by Technology
  • Table 22 Culture Diagnostics by Country
  • Table 23 Immunoassay Diagnostics by Country
  • Table 24 PCR Diagnostics by Country
  • Table 25 NGS Diagnostics by Country
  • Table 26 MS Diagnostics by Country
  • Table 27 Rapid, POC and Other Diagnostics by Country

Table of Figures

  • Figure 1 Pharmaceutical Spending History by Country
  • Figure 2 AMR and Antibiotic Introduction
  • Figure 3 The Death Toll of AMR
  • Figure 4 AMR Diagnostics - Key Countries
  • Figure 5 Chart of Share Change by Pathogen
  • Figure 6 Chart - DRSP Diagnostics by Country
  • Figure 7 Chart - DRC Diagnostics by Country
  • Figure 8 Chart - CD Diagnostics by Country
  • Figure 9 Chart - Infectious Disease Immunoassay by Country
  • Figure 10 Chart - DRNG Diagnostics by Country
  • Figure 11 Chart - DRNTS Diagnostics by Country
  • Figure 12 Chart of Growth by Technology
  • Figure 13 Chart - Technology Change in Planning Period
  • Figure 14 Chart - Bacterial Culture by Country
  • Figure 15 Chart - Immunoassay Diagnostics by Country
  • Figure 16 Chart - PCR Diagnostics by Country
  • Figure 17 Chart - NGS Diagnostics by Country
  • Figure 18 Chart - MS Diagnostics by Country
  • Figure 19 Chart - Rapid, POC and Other Diagnostics by Country
Back to Top
전화 문의
F A Q
 
BCC Research